You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, Colorectal Cancer Trial in Beijing (18F-FDG)

Recruiting
  • Lung Cancer
  • Colorectal Cancer
  • Beijing, China
    Beijing Cancer Hospital
Mar 27, 2023

Chronic Lymphocytic Leukemia Trial in Herlev (PD-L1, PD-L2 peptides with Montanide ISA51)

Completed
  • Chronic Lymphocytic Leukemia
  • PD-L1, PD-L2 peptides with Montanide ISA51
  • Herlev, Denmark
    Herlev Hospital
Feb 4, 2022

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Not yet recruiting
  • Advanced Solid Tumor
  • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 9, 2023

Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)

Not yet recruiting
  • Glioblastoma
  • (no location specified)
Sep 25, 2023

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Solid Tumor Trial (BS006 Injection)

Not yet recruiting
  • Solid Tumor
  • BS006 Injection
  • (no location specified)
Jul 3, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma Breast
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 29, 2022

Follicular Lymphoma Trial in Herlev (PD-L2 peptide, PD-L2 and PD-L1 peptide)

Completed
  • Follicular Lymphoma
  • PD-L2 peptide
  • PD-L2 and PD-L1 peptide
  • Herlev, RegionH, Denmark
    Herlev Hospital
Feb 23, 2021

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

NSCLC, Lung Diseases, Lung Tumors Trial in New Haven (Sitravatinib, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +8 more
  • New Haven, Connecticut
    Yale University
Oct 26, 2022

Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 9, 2023

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital, Fudan University
Mar 28, 2022

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Advanced NSCLC Trial (BNT116, Cemiplimab)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jan 3, 2023

Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Helsinki (TILT-123, Avelumab)

Recruiting
  • Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Helsinki, Finland
    Docrates Cancer Center
Jul 12, 2022

Urothelial Carcinoma Bladder, PD-1 Inhibitor Trial in Shanghai (Tislelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Urothelial Carcinoma Bladder
  • PD-1 Inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 15, 2022

Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma Trial in Houston (drug, behavioral, radiation)

Not yet recruiting
  • Squamous Cell Carcinoma
  • Oral Cavity Squamous Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8 Trial in Atlanta

Recruiting
  • Metastatic Non-Small Lung Cell Cancer
  • +4 more
  • Atlanta, Georgia
    Winship Cancer Institute of Emory University
Oct 19, 2022

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

Tumor Metastasis Trial in Canada, United Kingdom, United States (BI 754091, BI 754111, BI 836880)

Active, not recruiting
  • Neoplasm Metastasis
  • BI 754091
  • +2 more
  • La Jolla, California
  • +16 more
Jan 9, 2023